CSBio CSBio

X
[{"orgOrder":0,"company":"CordenPharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolo Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for Eosinophilic Esophagitis and Allergic Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Peptide","graph2":"CordenPharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.

            Lead Product(s): IRL201104

            Therapeutic Area: Gastroenterology Product Name: ‘1104

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Revolo Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY